metoprolol has been researched along with Lung Neoplasms in 3 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a prospective, randomized clinical study to assess whether prophylactic treatment with metoprolol or losartan, initiated soon after lung cancer surgery in patients with elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, reduces the incidence of postoperative atrial fibrillation." | 5.22 | Prevention of Atrial Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery: The PRESAGE Trial. ( Bacchiani, G; Beggiato, M; Cardinale, D; Casiraghi, M; Cipolla, CM; Civelli, M; Colombo, A; Colombo, N; Lamantia, G; Meroni, CA; Salvatici, M; Sandri, MT; Spaggiari, L; Tedeschi, I; Veglia, F; Venturino, M, 2016) |
| "Metoprolol tartrate was subsequently discontinued and the ALT and AST gradually decreased and the patient discharged from the hospital eight days later with his liver function improved." | 1.91 | Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinib. ( Dong, Z; Fang, L; Lian, Y; Qiu, X; Ren, B, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Qiu, X | 3 |
| Ren, B | 3 |
| Lian, Y | 3 |
| Fang, L | 3 |
| Dong, Z | 3 |
| Cardinale, D | 1 |
| Sandri, MT | 1 |
| Colombo, A | 1 |
| Salvatici, M | 1 |
| Tedeschi, I | 1 |
| Bacchiani, G | 1 |
| Beggiato, M | 1 |
| Meroni, CA | 1 |
| Civelli, M | 1 |
| Lamantia, G | 1 |
| Colombo, N | 1 |
| Veglia, F | 1 |
| Casiraghi, M | 1 |
| Spaggiari, L | 1 |
| Venturino, M | 1 |
| Cipolla, CM | 1 |
| Friedman, GD | 1 |
| Udaltsova, N | 1 |
| Habel, LA | 1 |
1 trial available for metoprolol and Lung Neoplasms
| Article | Year |
|---|---|
Prevention of Atrial Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery: The PRESAGE Trial.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Incidence; Losartan; Lung Neoplas | 2016 |
2 other studies available for metoprolol and Lung Neoplasms
| Article | Year |
|---|---|
Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug In | 2023 |
Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug In | 2023 |
Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug In | 2023 |
Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug In | 2023 |
Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug In | 2023 |
Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug In | 2023 |
Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug In | 2023 |
Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug In | 2023 |
Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug In | 2023 |
Norepinephrine antagonists and cancer risk.
Topics: Atenolol; Breast Neoplasms; Clonidine; Colonic Neoplasms; Female; Humans; Lung Neoplasms; Male; Meto | 2011 |